Jump to content
NEW Coronavirus Forum! Stay safe by staying at home! Be well! ×
GET YOUR FLU VACCINE!

Search the Community

Showing results for tags 'Benlysta'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • The LuPUS Message Board
    • Announcements
    • What is the LuPUS Message Board?
    • A Welcome to New Members
    • User Problems
    • Links
  • Medical
    • Medical News 2003
    • Medical News 2004
    • Medical News 2005
    • Medical News 2006
    • Medical News 2007
    • Medical News 2008
    • Medical News 2009
    • Medical News 2010
    • Medical News 2011
    • Medical News 2012
    • Medical News 2013
    • Medical News 2014
    • Medical News 2015
    • Medical News 2016
    • Medical News 2017
    • Medical News 2018
    • Medical News 2019
    • Medical News 2020
    • Coronavirus: COVID-19
    • Medication & Therapy
    • Lupus and Pregnancy
    • Sjögren’s syndrome
    • Lymphoedema
    • Marginal Zone Lymphoma
  • Non-Medical
    • LuPUS Message Board
  • Public
    • Guest & Test Messages
    • Free Offers
    • Contributors

Blogs

  • Admin
  • Admin
  • Changes To My Diet For Health Reasons

Categories

There are no results to display.

There are no results to display.


Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


AIM


MSN


Website URL


ICQ


Yahoo


Jabber


Skype


Surname (Last or Family name)


First name


Date of Birth


Country


Location


Interests

Found 5 results

  1. Benlysta Treatment Lowers Disease Activity for SLE Patients, Real-world Data Shows MAY 29, 2020 BY INES MARTINS, PHD Treatment with Benlysta (belimumab) induces meaningful and long-lasting reductions in systemic lupus erythematosus (SLE) disease activity, helping a significant proportion of patients achieve durable remission or a status of low disease activity, a study in a real-world Italian population shows. Patients diagnosed in the prior two years, with low da
  2. Benlysta Formulation for Lupus Gets FDA Nod August 01, 2017 | Lupus By Rheumatology Network Staff A new subcutaneous formulation of Benlysta (belimumab) has received FDA approval for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy, GSK announced. This is the first subcutaneous self-injection treatment option for patients with SLE, according to GSK. Patients will be able to administer the medicine
  3. GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus Issued: London, UK GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients with active, autoantibody‑positive SLE who are receiving standard therapy. Systemic Lupus Erythematosus (SLE) is the most common f
  4. Benlysta: first targeted lupus treatment 01 November 2011, 9:14am Benlysta (belimumab) is licensed as add-on therapy in patients with autoantibody-positive systemic lupus erythematosus (SLE) who have high disease activity despite standard treatment. Benlysta must be administered in hospital PHARMACOLOGY Belimumab is a monoclonal antibody specific for the soluble human B lymphocyte stimulator protein, BLyS. It inhibits the differentiation of B cells into antibody-producing plasma cells.1 CLINICAL STUDIES Two pivotal randomised trials showed that the addition of belimumab t
  5. NICE draft guidance provisionally denies funding for lupus treatment Benlysta on the NHS Posted 05.10.2011 Draft guidance issued last Friday by the National Institute for Health and Clinical Excellence (NICE) does not recommend Benlysta (belimumab) for patients with active autoantibody positive systemic lupus erythematosus (SLE) in England and Wales because it does not consider it to be a cost-effective use of National Health Service (NHS) resources. Belimumab was granted marketing authorisation by the European Commission in July 2011 in adult patients with SLE, w
×
×
  • Create New...

Important Information